AZN AstraZeneca PLC

   By Adria Calatayud 
 

AstraZeneca PLC said Tuesday that a phase III trial for its Tagrisso drug showed "overwhelming efficacy."

The FTSE 100-listed pharmaceutical company said the trial in the adjuvant treatment of patients with epidermal growth factor receptor-mutated lung cancer will be unblinded early following a recommendation from an Independent Data Monitoring Committee based on its determination of overwhelming efficacy.

The primary endpoint of the trial is disease-free survival, for which Tagrisso was assessed against placebo for a treatment duration of up to three years, AstraZeneca said. The trial will continue to assess the secondary endpoint of overall survival, the company said.

Furthermore, AstraZeneca and Merck & Co., Inc. said the U.S. Food and Drug Administration has approved the kinase inhibitor Koselugo for the treatment of pediatric patients two years of age and older with neurofibromatosis type 1 who have symptomatic, inoperable plexiform neurofibromas, a rare and debilitating genetic condition.

Write to Adria Calatayud at adria.calatayud@dowjones.com

(END) Dow Jones Newswires

April 14, 2020 02:35 ET (06:35 GMT)

Copyright (c) 2020 Dow Jones & Company, Inc.